.  .
͡ .

䫵 KnowSteroid

Facebook ɳ

Facebook ´
Facebook Twitter
Youtube .


Ѻا : 7/03/2018
Online User Last 1 hour (0 users)

  Govt moves to make three key cancer drugs cheaper
  12 Ҥ 2556

Date: 12 January 2013

Abantika Ghosh : New Delhi, Sat Jan 12 2013, 10:15 hrs

In a move that will benefit thousands of cancer patients but is likely to upset pharma MNCs, the Department of Pharmaceuticals has started the process of issuing compulsory licences for three commonly used anti-cancer drugs, Trastuzumab (or Herceptin, used for breast cancer), Ixabepilone (used for chemotherapy) and Dasatinib (used to treat leukaemia).

Compulsory licensing (CL) by the government allows a domestic company to manufacture and sell a generic version of a patented drug with or without the consent of the patent-holder. Sections 84 and 92 of the Indian Patents Act, 1970, provide for CL in cases where the patented drug is unavailable, unaffordable, or if there are problems with its supply in India. CL reduces the price of a drug manifold, and is a practice in many developing countries.

The first drug to be issued a compulsory licence in India was Bayers Nexavar (sorafenib tosylate), a drug for liver cancer, last August. After the CL, Nexavar is available for Rs 8,880 per pack of 120 tablets (a months dose), over 95% cheaper than its pre-CL price.

Trastuzumab, Ixabepilone and Dasatinib are all more expensive that Nexavar, costing Rs 50,000, Rs 70,000-80,000 and Rs 15,000 respectively for a months dose.

Officials at the Department of Pharmaceuticals said it was too early to predict the post-CL price of these drugs. Dr Shyam Aggarwal, consultant oncologist at Sir Ganga Ram Hospital, said, Even after the recent cut in the prices of Trastuzumab and Dasatinib, they are still way too expensive for the common man. It is a very good move and will not just benefit Indians but possibly also bring down cancer drug prices in countries where the pharma market is not controlled by the US and western European nations.